FDA Delivers Latest CBD Study to Congress

On July 8, 2020, the U.S. Food and Drug Administration (“FDA”) delivered the results of its most comprehensive sampling study on the current cannabidiol (“CBD”) marketplace to the U.S. House Committee on Appropriations and the U.S. Senate Committee on Appropriations.1 Congress mandated FDA to … Read more about FDA Delivers Latest CBD Study to Congress